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OBJECTIVES The goal of this study was to evaluate whether quantitation of thrombus burden with
transesophageal echocardiography (TEE) can help risk-stratify patients undergoing throm-
bolysis of prosthetic valve thrombosis (PVT).
BACKGROUND Thrombolytic therapy of PVT has an unpredictable risk of embolization and complications.
METHODS An international registry of patients with suspected PVT undergoing two-dimensional/
Doppler and TEE before thrombolysis was established. All TEE studies were reviewed and
quantitated by a single observer blinded to all data.
RESULTS From 1985 to 2001, 107 patients (71 females; age 24 to 86 years) from 14 centers (6 in the
U.S.) were identified. The majority of cases involved the mitral valve (79 mitral, 13 aortic, and
15 tricuspid). Hemodynamic success rate was achieved in 85% and was similar across valves.
Overall complications were observed in 17.8%, and death in 5.6%. Predictors of complications
were: New York Heart Association (NYHA) functional class, presence of shock, sinus
tachycardia, hypotension, previous history of stroke, thrombus extension beyond the valve
ring, and thrombus area. Multivariate analysis demonstrated that two variables were
independent predictors of complications: thrombus area by TEE (odds ratio [OR] 2.41 per
1 cm2 increment, 95% confidence interval [CI] 1.12 to 5.19) and prior history of stroke (OR
4.55, 95% CI 1.35 to 15.38). A thrombus area 0.8 cm2 identified patients at lower risk for
complications from thrombolysis, irrespective of NYHA functional class.
CONCLUSIONS In PVT, the thrombus size imaged with TEE is a significant independent predictor of
outcome. Transesophageal echocardiography can identify low-risk groups for thrombolysis
irrespective of symptom severity and is therefore recommended in the management of
prosthetic valve thrombosis. (J Am Coll Cardiol 2004;43:77–84) © 2004 by the American
College of Cardiology Foundation
Prosthetic valve thrombosis (PVT) is an infrequent but
potentially life-threatening complication, with a reported
incidence of 0.5% to 8% of left-sided valves and up to 20%
of tricuspid valves (1–3). Although re-operation has been
the traditional treatment for PVT, it is associated with
significant morbidity and mortality, particularly in very
symptomatic individuals (4–7). Since the first report of
Luluaga et al. (8), intravenous thrombolytic therapy has
emerged as an alternative to re-operation. The potential risk
of cerebral thromboembolism, however, has limited its use
in left-sided PVT. Case reports and case series have varied
widely in the rate of success and, particularly, in the
morbidity and mortality associated with thrombolysis (9–
20). Accordingly, recommendations for thrombolysis in
left-sided PVT have varied from first-line therapy
(10,12,21) to poor operative candidates or patients who
refuse surgery (4,9,14,22).
Transesophageal echocardiography (TEE) is currently
the test of choice for evaluating the mechanism of prosthetic
valve obstruction (23) and allows the quantitation of
thrombus burden (24,25). Whether TEE is helpful in
identifying structural or functional parameters that can
risk-stratify patients undergoing thrombolysis has not been
previously investigated. In the present study, we sought to
explore the role of TEE, in addition to clinical and
echocardiographic parameters, in predicting the safety and
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efficacy of thrombolysis of PVT and to assess the thrombus
burden beyond which complications are increased with
thrombolysis.
METHODS
Patient population. An international registry of patients
with suspected PVT undergoing two-dimensional/Doppler
and TEE before thrombolysis was established. Major na-
tional and international echocardiography laboratories were
contacted for this purpose. Inclusion criteria included all the
following: 1) suspected prosthetic valve thrombosis with the
presence of prosthetic valvular obstruction by Doppler
echocardiography or thrombus formation on the valve by
TEE with or without obstruction; 2) availability of TEE
before thrombolysis; and 3) subsequent treatment with
thrombolysis.
A detailed questionnaire to the participating centers
captured the following: patient characteristics (age, gender,
date of valve implantation, model, size, and position),
clinical presentation (symptoms including New York Heart
Association [NYHA] functional class, embolic phenomena,
angina, symptom duration, and anticoagulation status),
history of hypertension, diabetes, coronary artery disease,
and peripheral vascular disease. Transthoracic two-
dimensional and Doppler examination reports were also
requested including valvular gradients before and within one
to two weeks after thrombolysis, the treatment protocol
used, clinical outcome, and complications. All centers were
asked to provide tapes of the TEE studies performed before
thrombolysis for review and quantitation.
Echocardiographic analysis. All TEE tapes were sent to
the echocardiography laboratory at Baylor College of Med-
icine and were reviewed and quantitated by a single observer
(A.T.) blinded to all clinical data and outcomes. The size of
the mass on the prosthetic valve was quantitated (largest
length and area of the mass from any TEE view). The mass
was also evaluated for mobility, extension beyond the valve
ring onto adjacent structures (atrial wall, aorta), and ultra-
sound intensity (soft or dense), as previously described (24).
Inter- and intra-observer variability in evaluating mass
characteristics was performed on a randomly selected sub-
group of patients.
Definition of outcome. Both hemodynamic and clinical
outcome were assessed within one week and up to two
weeks after thrombolysis. “Complete hemodynamic success”
was defined as return of the transvalvular gradient to
normal range for the particular prosthesis (26), whereas
“partial hemodynamic success” was defined as partial im-
provement in gradient without complete normalization.
“Clinical success” was defined as hemodynamic success
without clinical complications, because instances of major
complications in the presence of hemodynamic success
could occur.
Recorded complications of thrombolytic therapy included
death, intracranial bleed, stroke, transient cerebral ischemic
attacks, peripheral embolic events, coronary emboli, and
bleeding requiring transfusions. All central nervous system
complications were documented by neurological examina-
tion and evaluated with computed tomography.
Statistical analysis. Results are shown as mean SD. The
chi-square test was used for the comparison of discrete
variables. The Student t test and Wilcoxon rank-sum
two-sample test were used, respectively, for continuous
variables that were (blood pressure (BP), heart rate, and
gradients) and were not (other variables) normally distrib-
uted. Kruskal-Wallis analysis of variance on ranks was used
to compare outcomes among 3 groups because variables
were not normally distributed. If analysis of variance dem-
onstrated significance, Dunn’s multiple comparison proce-
dure was performed. Logistic regression analysis was used to
assess the strength of associations of various factors with
clinical success, complications, and embolic risk. Linear
correlation between intra- and inter-observer measurements
of thrombus area was performed with Pearson’s product
moment correlation. The receiver operating characteristic
curve of thrombus mass size for predicting complications
was plotted. The best cut-off was defined as the one
providing high sensitivity with a moderate specificity for
events, as is desirable clinically. Statistical significance was
set at p  0.05. SAS System for Windows 8.0 was used for
analysis.
RESULTS
Patient population. Fifty-five national and international
centers were contacted, of which 14 had cases that ful-
filled study entry criteria (Appendix). At the participating
centers, there were a total of 107 cases (Table 1) from 1985
to 2001 with suspected PVT in which a TEE was per-
formed before thrombolysis. In some centers, thrombolysis
was the first-line therapy regardless of TEE findings such as
size or mobility of the thrombus (two centers including 38
patients), whereas in others, thrombolysis was not standard
therapy; selected patients included those who had contra-
indications to surgery, were poor surgical candidates, or
refused surgery. The majority of patients were in NYHA
class III to IV (63.5%); 5% were asymptomatic, with the
diagnosis being made through routine echocardiography.
Thrombolytic treatment. The thrombolytic agents used
are listed in Table 1. Streptokinase was given as a slow
infusion over 12 to 48 h, with occasional extension to 72 to
120 h. Urokinase was given as slow infusion over 6 to 48 h.
Abbreviations and Acronyms
BP  blood pressure
CI  confidence interval
NYHA  New York Heart Association
OR  odds ratio
PVT  prosthetic valve thrombosis
TEE  transesophageal echocardiography
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Recombinant tissue plasminogen activator was administered
as 10 mg bolus followed by 90 mg infusion over 2 to 6 h.
Intravenous heparin infusion was usually resumed after the
completion of thrombolysis. Allergic reaction to streptoki-
nase occurred in three patients requiring switching to
urokinase.
Echocardiographic characteristics of PVT and relation-
ship to clinical presentation. The TEEs were performed
with either multiplane (81.3%) or biplane (15%) probes;
monoplane was used in only four patients, all of whom had
thrombus visualized. A definite mass on the prosthesis was
seen in 86.0% (Table 2); the largest thrombus area was
14.7 cm2. The inability to visualize a mass on an obstructed
valve is usually associated with a small thrombus or pannus
affecting the hinge of the prosthesis (24) and was encoun-
tered similarly for aortic and mitral valves (15.4% and
13.9%, respectively). Overall, the prosthetic gradient was
elevated before thrombolysis compared with normal values
(Table 2). Thrombus burden, in general, was largest for
mitral valves. Thrombi without significant hemodynamic
obstruction were observed in 14 patients. In general, these
were smaller than those with hemodynamic obstruction,
especially for the mitral position, and were more often
mobile. Non-obstructive thrombi were also less likely to be
associated with the presence of NYHA class IV (0% vs.
20.4%, p  0.0001) and more likely to be associated with a
history of prior stroke (57.1% vs. 20.5%, p  0.004) and
presentation with a stroke (71.4% vs. 2.2%, p  0.0001).
Inter- and intra-observer variability in mass evaluation
was performed in 14 randomly selected patients (10 mitral,
3 aortic, and 1 tricuspid). The mean maximal mass area was
1.21 cm2, with a range of 0 to 4.94 cm2. Intra- and
inter-observer concordance in classifying echo density of the
mass was 93%. The intra- and inter-observer mean differ-
ence in area was 0.04  0.03 cm2 and 0.12  0.16 cm2,
respectively. Excellent linear correlations were observed for
intra- and inter-observer measurements of mass area (r 
0.97 and 0.95, respectively).
Predictors of success of thrombolytic therapy. HEMO-
DYNAMIC SUCCESS. After thrombolytic therapy, a signifi-
cant decrease in gradient was seen (Table 2). Complete
hemodynamic success was achieved in 76.3% of the 93
obstructed valves and was similar among different valves and
lytic agents (Table 3). Partial hemodynamic success was
infrequently seen (8.6%). Clinical and hemodynamic
variables did not influence the rate of hemodynamic success.
An obstructive soft mass by TEE (n  59) was associated
with a very high degree of hemodynamic success (91.5%).
Although hemodynamic success was lower when a dense
mass was seen (n  20, p  0.053), it was still high (75%).
In the 14 cases with obstruction but without obvious
mass, hemodynamic success was also high (85.7%).
Using logistic regression analysis that considered a number
of variables (age, gender, presenting systolic pressure and
heart rate, NYHA functional class, prior history of stroke,
thrombus area, the echodensity and mobility of the mass),
a soft mass by TEE was the single predictor of hemo-
dynamic success, p  0.029. Of the 14 patients with
hemodynamic failure, nine were referred for surgery within
two to 13 days after thrombolysis. At surgery, four patients
were found to have pannus with thrombus, one patient had
entrapment of chordae, and four had obstructive thrombi.
There were no postoperative deaths. The remaining five
patients without hemodynamic improvement did not un-
dergo surgery because of complications (n  2) or poor
clinical status.
CLINICAL SUCCESS. Clinical success was achieved in 73.8%
and was best for tricuspid prostheses (Table 3). Clinical
Table 1. Clinical Characteristics of the 107 Patients With
Prosthetic Valve Thrombosis
Age (yrs) 54.2  15.8 (24–86)
Gender (male/female) 36/71
Median time since valve replacement (days) 33 (0.25–288)
Valve
Mitral 79 (73.8)
Aortic 13 (12.2)
Tricuspid 15 (14.0)
Type of prosthetic valve
Bileaflet 83 (77.6)
Tilting disc 23 (21.5)
Porcine 1 (0.9)
Median duration of symptoms (days) 7 (0.125–270)
7 days 59 (55.1)
On anticoagulation 99 (93.4)
INR on admission 2.5 33 (32.4)
Aspirin use 78 (75%)
Atrial fibrillation 41 (39.4)
Systolic blood pressure on presentation (mm Hg) 119.5  18.9
Heart rate on presentation (beats/min) 91.7  21.3
NYHA class on presentation
I 14 (13.1)
II 25 (23.4)
III 49 (45.8)
IV 19 (17.7)
Presenting symptoms
Dyspnea 98 (91.1)
Shock 3 (2.8)
Angina 6 (15.1)
Cardiac arrest 1 (0.94)
Cerebrovascular accident 12 (11.3)
Peripheral emboli 5 (4.7)
Asymptomatic 5 (4.7)
Previous condition
Stroke 26 (24.3)
Emboli 11 (11.2)
Hypertension 19 (19.6)
Diabetes 16 (16.3)
Coronary artery disease 18 (18.4)
Peripheral vascular disease 8 (8.3)
Thrombolytic used
Streptokinase 58 (54.7)
Urokinase 18 (17.0)
Tissue plasminogen activator 31 (28.9)
Second agent required 25 (23.8)
Data shown as n (% of patients with reported data), mean  SD or median (range)
where appropriate.
INR  international normalized ratio; NYHA  New York Heart Association.
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success was associated with smaller thrombi (0.60  0.60
cm2 vs. 1.91  2.95 cm2, p  0.027), lower incidence of
prior stroke (16.5% vs. 46.4%, p  0.0015), and higher
diastolic BP at presentation (72.7  9.1 mm Hg vs. 65.6 
14.7 mm Hg, p  0.0078). Presentation with shock was
associated with clinical failure (10.7% vs. 0%, p  0.0032),
mostly from clinical complications. Less severe NYHA
functional class had a trend toward higher clinical success
rate (Table 4). In a logistic regression analysis model, after
adjusting for age, gender, and presenting BP, smaller
thrombus area by TEE (odds ratio [OR] 0.41/cm2, 95%
confidence interval [CI] [0.20 to 0.82]) and lack of prior
history of stroke (OR 0.29, 95% CI [0.10 to 0.86]) were
independent variables associated with clinical success.
Predictors of complications of thrombolytic therapy.
Complications within the first week of thrombolysis oc-
curred in 19 (17.8%) patients (Table 5); 18 in mitral valves
and one in an aortic valve (coronary emboli). No apparent
clinical complications occurred in the tricuspid valve group,
although lung perfusion or computed tomography scans
were not performed to document subclinical pulmonary
embolism. The left-sided embolic complication rate was
14%. The major complication rate, combining end points of
death, stroke, myocardial infarction, cerebral bleeding, and
peripheral emboli requiring intervention was 9.3%. Six
patients (5.6%) died within the first week after thromboly-
sis, all of whom had major complications before death. All
deaths were in the mitral valve group.
All clinical and echocardiographic parameters (Tables 1
and 2) were analyzed as possible predictors of complications.
Univariate predictors of all complications are listed in Table
6. Patients with a previous stroke (range 0.5 to 240 months,
median 6.0) had a higher incidence of complications.
However, in the few patients presenting with acute non-
hemorrhagic stroke (n  12), there was no increase in
complication or death rates (8.3% and 0%, respectively). In
Table 2. TEE and Doppler Findings in the 107 Patients With Prosthetic Valve Thrombosis
Aortic
(n  13)†
Mitral
(n  79)†
Tricuspid
(n  15)† p Value
Thrombus characteristic at TEE
Mass visualized on valve 11 (84.6) 68 (86.1) 13 (86.7) NS
Non-obstructive thrombus 2 (15.4) 12 (15.2) 0 NS
Thrombus area (cm2) 0.45  0.07 0.39  0.28 NS
Mobility (%) 2 (100) 9 (81.8) NS
Obstructive thrombus 11 (84.6) 67 (84.8) 15 (100) NS
Thrombus area (cm2) 0.68  0.54 1.13  2.06 0.77  0.71 NS
Mobility (%) 6 (66.7) 26 (45.6) 10 (66.7) NS
Extension beyond valve (%) 1 (7.7) 11 (13.9) 4 (26.7) NS
Moderate regurgitation (%) 3 (23.1) 8 (10.1) 7 (46.7) 0.002
Soft ultrasound density of mass 4 (30.8) 50 (63.3) 12 (80.0) 0.008
Prosthetic valve gradients
Mean gradient pre-lytic all valves (mm Hg) 40.1  18.2 13.4  7.5 11.8  3.11  0.0001*
Mean gradient post-lytic all valves (mm Hg) 24.8  23.4 4.7  2.5 3.7  1.5
Mean gradient pre-lytic bileaflet (mm Hg) 41.9  21.6 13.1  7.5 11.9  3.2  0.0001*
Mean gradient post-lytic bileaflet (mm Hg) 26.2  29.2 4.7  2.6 3.7  1.7
Mean gradient pre-lytic tilting disc (mm Hg) 37.2  12.6 14.8  7.6 11.0  2.8  0.0001*
Mean gradient post-lytic tilting disc (mm Hg) 22.6  11.8 4.9  1.9 3.5  0.7
*Prethrombolysis vs. postthrombolysis gradients for each valve location and type; †numbers denote all valves in that position.
NS  not significant; TEE  transesophageal echocardiography.
Table 3. Early Outcome of Thrombolytic Therapy
Overall
(n  107)
Aortic
(n  13)†
Mitral
(n  79)†
Tricuspid
(n  15)† p Value
Any hemodynamic success (%)* 79 (85.0) 8 (72.7) 56 (83.6) 15 (100) NS
Complete hemodynamic success (%)* 71 (76.3) 7 (63.6) 50 (74.6) 14 (93.3) NS
Partial hemodynamic success (%)* 8 (8.6) 1 (9) 6 (8.9) 1 (6.7) NS
Clinical success (%) 79 (73.8) 9 (69.2) 55 (69.6) 15 (100) 0.04
Obstructive thrombus (%) 7 (63.6) 46 (68.7) NS
Non-obstructive thrombus (%) 2 (100) 9 (75.0) NS
Any complication (%) 19 (17.8) 1 (7.7) 18 (22.8) 0 (0) 0.06
Obstructive thrombus (%) 1 (9.1) 16 (23.8) NS
Non-obstructive thrombus (%) 0 (0) 2 (16.7) NS
Death (%) 6 (5.6) 0 (0) 6 (7.6) 0 (0) NS
Repeat valve surgery (%) 9 (8.4) 2 (15.4) 7 (8.9) 0 (0) NS
*Includes only patients with obstructive thrombus (overall  93; aortic  11; mitral  67; tricuspid  15); †numbers denote all valves in that position.
NS  not significant.
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these patients, the thrombus size was small (0.45  0.24
cm2). Thrombus size in patients with complications aver-
aged 2.41  3.48 cm2, while in patients without complica-
tions it was 0.63  0.60 cm2 (p  0.039). Using receiver
operating characteristic curve analysis, the best cut-off of
thrombus size for predicting complications was 0.8 cm2
(sensitivity 79%, specificity 68%). Figure 1 shows the
relation of complication rate and death rate with increasing
thrombus area. The 0.8 cm2 cut-off was applicable to both
mitral and aortic valves as well as bileaflet or tilting disc
valves (complication rate of small vs. large thrombi: mitral,
8.5% vs. 43.8%; aortic, 0% vs. 25%; tilting disc, 6.7% vs.
14.3%; bileaflet, 7.3% vs. 48.3%). In a logistic regression
analysis model, after adjusting for age, gender, and NYHA
functional class, two variables were independent predictors
of complications: larger thrombus area by TEE and prior
history of stroke (Fig. 2). An increase of 1 cm2 in thrombus
size was associated with a 2.4-fold increase in complication
rate (OR 2.41/cm2, 95% CI 1.12 to 5.19), and a prior
history of stroke was associated with a 4.5-fold increase in
complication rate (OR 4.55, 95% CI 1.35 to 15.38). The
history of stroke was most relevant for complications in
patients with large thrombi. In patients with prior history of
stroke and small thrombus 0.8 cm2 (n  12), there were
no complications or death. On the other hand, in patients
with large thrombus 0.8 cm2 and prior history of stroke
(n  14), the complication rate was 78.6%. In patients with
large thrombus 0.8 cm2 but no prior history of stroke
(n  29), the complication rate was 13.8%.
Thrombus area was a predictor of outcome, irrespective
of functional class (Fig. 3). Patients with NYHA class I to
II and small thrombus area had the best outcome, with no
complications or death. Patients with functional class III to
IV and small thrombi had a lower complication rate (10.8%)
and death rate (5.4%) than patients with larger thrombi of
similar functional class.
There was no difference between patients with aortic or
mitral PVT with regard to duration of symptoms, present-
ing BP or heart rate, success rate, or complications. As the
majority of complications occurred in mitral valves, the
mitral valve group was analyzed separately. As expected,
similar univariate predictors of complications were seen. In
a multivariate logistic model, the same independent predic-
tors of complications emerged: thrombus size by TEE (OR
2.76/cm2, 95% CI 1.23 to 6.22) and prior history of stroke
(OR 4.62, 95% CI 1.37 to 15.59).
DISCUSSION
The present study is the first to evaluate whether TEE can
help predict the success of thrombolysis and improve risk
stratification of patients undergoing thrombolysis for PVT.
Thrombus size determined by TEE was a significant deter-
minant of clinical outcome and complications, irrespective
of functional class. This prognostic power of imaging was
additive to that of clinical parameters, namely previous
stroke.
Thrombolysis of PVT: hemodynamic vs. clinical success.
Thrombolysis of PVT has emerged as an alternative to
surgery by circumventing the risks of re-operation (4) but
carries inherent complications. In recent reviews (15,27) and
in a series of 110 patients by Gupta et al. (18), hemody-
namic improvement was seen in the majority (70%) of
cases, with a complication rate of 12% to 24%, and a death
rate of 6% to 10%. In the study by Gupta et al. (18), atrial
fibrillation was reported as a risk for embolic complication.
However, only 16.4% of cases underwent TEE before
thrombolysis, thus precluding the evaluation of whether
thrombus burden impacts clinical outcome.
The availability of TEE in this international registry
allows for the first time the examination of the role of
thrombus characteristics in the outcome of thrombolysis.
The rate of hemodynamic success and complications, sim-
ilar to previously published reports without TEE imaging,
supports that this registry is quite representative of patients
undergoing thrombolysis. Thrombus burden was found to
be an independent predictor of clinical success, in addition
to a history of stroke. The history of stroke, however,
appeared to be relevant and additive in predicting poor
Table 4. Outcome of Thrombolytic Therapy According to NYHA Class at Presentation
NYHA Class n
Thrombus Area
(cm2)*
Hemodynamic
Success
(%)
Clinical
Success
(%)
Any
Complication
(%)
Embolic
Complication
(%)†
Death
(%)
Class I 14 0.51  0.36 (0–1) 92.9 71.4 21.4 15.4 0
Class II 25 0.61  0.71 (0–3) 88.0 80.0 8.0 4.2 0
Class III 49 0.86  1.06 (0–6.5) 85.7 77.6 14.3 14.3 8.2
Class IV 19 1.89  3.4 (0.1–14.7) 84.2 57.9 36.8 29.4 10.5
*Analysis of variance (ANOVA) p  0.04; class IV vs. others p  0.05; †ANOVA p  0.075.
NYHA  New York Heart Association.
Table 5. Complications of Thrombolytic Therapy of Prosthetic
Valve Thrombosis in 107 Patients
Type of Complication n (%)
Peripheral emboli 4 (3.7)
Central nervous system bleeding 2 (1.9)
Stroke 3 (2.8)
Transient ischemic attack 3 (2.8)
Coronary emboli 3 (2.8)
Bleeding requiring transfusion 4 (3.7)
Death 6 (5.6)
All embolic complications 15 (14.0)
Any complication 19 (17.8)
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outcome only when thrombus size was large. One possible
explanation is that patients with prior history of stroke are at
increased risk and sicker clinically to start with. Thrombol-
ysis of a large thrombus with a higher potential for embo-
lization lead to worse outcome in this setting. On the other
hand, nonobstructive small thrombi were more likely to be
associated with presentation with a stroke, before throm-
bolysis. Although the number of patients with small non-
obstructive thrombi presenting with stroke is relatively small
to allow firm conclusions about safety, they appear to have
low complication rate with thrombolysis, similar to the
whole cohort of patients with small thrombi.
Using receiver operating characteristic analysis, the best
cut-off of thrombus area for predicting complications was
0.8 cm2, with the risk of complications increasing signifi-
cantly with larger thrombus burden. Of interest is the
discrepancy between determinants of hemodynamic and
clinical success. Whereas a larger thrombus was associated
with clinical complications, the alleviation of obstruction
was independent of thrombus burden.
Severity of clinical presentation, thrombus burden, and
clinical outcome. Patients presenting with symptoms of
advanced heart failure in the setting of PVT have a worse
clinical outcome, irrespective of treatment modality (9,13).
Whereas the reported mortality with thrombolysis is very
low (0%) in minimally symptomatic patients (27), it is
significantly higher in patients with functional class III and
IV (11.9% and 13%, respectively). Patients with cardiogenic
shock appear to fare even worse. The present series, the
largest to evaluate outcome of patients with advanced
symptoms and known thrombus burden, demonstrates that
patients with severe heart failure indeed have poor outcome,
and yet have similar hemodynamic success compared with
those with lesser symptoms. The worse clinical outcome was
observed in patients with large thrombi, irrespective of
severity of symptoms (Fig. 3). Thus, the observed higher
complication and death rate in hemodynamically compro-
mised patients is likely due to a combination of the severity
of the clinical condition and, importantly, the size of the
thrombus.
Thrombolysis versus surgery for PVT: identifying a
low-risk group for thrombolysis. The optimal therapy for
PVT is still debated. In the absence of randomized trials,
the choice of thrombolysis versus surgery is driven by a
historical comparison of the respective risks in similar
patient subsets (4,7,12,22,28–30). Surgical mortality of
valve re-operation has been related to the severity of clinical
presentation—similar to thrombolysis, but, in addition, to
other risks such as ventricular dysfunction and renal failure
(30). Whereas in patients with NYHA class I to III surgical
mortality can be low (4.7%) (4), those with functional class
Table 6. Univariate Predictors of Any Complication After Thrombolysis
Parameters
Complication
(n  19)
No Complication
(n  88) p Value
Clinical parameters
Previous history of stroke 57.9% 17.1% 0.0002
Presence of shock 15.8% 0% 0.0002
NYHA class IV at presentation 36.8% 13.6% 0.016
Systolic blood pressure (mm Hg) 110  22.8 121.9  17.1 0.016
Heart rate (beats/min) 101.6  19.1 88.3  21.2 0.035
Echocardiographic parameters
Thrombus size 0.8 cm2 78.9% 31.8% 0.0001
Extension of thrombus beyond valve 36.8% 10.2% 0.003
Soft ultrasound density of mass 94.4% 66.2% 0.017
NYHA  New York Heart Association.
Figure 1. Relationship of thrombus area by transesophageal echocardiog-
raphy to overall complication rate and death rate. *p 0.003; **p 0.0001
versus thrombus area0.8 cm2; p 0.016 and p 0.07 versus thrombus
area 0.8 cm2 and 0.8 to 1.59 cm2, respectively.
Figure 2. Incidence of complication rate and death rate according to the
presence or absence of the two risk factors (RF) of thrombus area0.8 cm2
and previous stroke.
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IV symptoms or shock have a high mortality (17% to 41%),
particularly if surgery is urgent (7).
In 1998, the American College of Cardiology/American
Heart Association valve disease guidelines (31) reserved
thrombolysis for patients in NYHA class III and IV who
presented a high surgical risk or had contraindications to
surgery, and for patients with “small clot” and NYHA class
I to II who fail treatment with heparin. There were no
available data to define what constituted a small clot. The
present investigation validates these recommendations and
further refines them by providing the threshold of thrombus
burden (0.8 cm2) beyond which complications with throm-
bolysis increase. Patients in functional class I to II and a
small thrombus 0.8 cm2 have essentially no or minimal
complications with thrombolysis. In contrast, patients in
functional class I to II and larger thrombi have a high
complication rate and should undergo surgery unless there
are contraindications. The present study also shows the
importance of quantitating thrombus burden even in pa-
tients with functional class III to IV. In this subgroup with
historically high surgical mortality, a small thrombus by
TEE identifies patients with relatively low complication and
death rates and who, therefore, may benefit from throm-
bolysis as first-line therapy. Considering that some patients
in this registry have received thrombolytic therapy because
of poor surgical risk gives more credence to these recom-
mendations. On the other hand, patients in functional class
III to IV with larger thrombi need assessment of total
surgical risk. Repeat surgery is generally indicated unless the
surgical risk is higher than that of thrombolysis. Further
confirmation of these recommendations requires a prospec-
tive randomized trial of surgery versus thrombolytic therapy
for PVT.
Study limitations. Because of its retrospective design, our
study may be subject to selection bias. However, the success
and complication rates observed are similar to those re-
ported in thrombolytic series without TEE. Thrombolysis
was used as first-line therapy in some centers irrespective of
high-risk TEE findings, whereas, in others, it was reserved
for those too unstable for surgery. This different approach
may actually have helped assess the risk of different size
thrombi, including large ones, as most patients were not
excluded based on TEE findings. The majority of valves
undergoing thrombolysis were bileaflet mechanical prosthe-
ses in the mitral position, and, therefore, the current
findings are most applicable to this valve type and position.
Finally, the thrombolytic regimens used were different
among centers. Although firm conclusions as to the most
effective and safest protocol could not be ascertained, the
efficacy of thrombolysis with different agents appears to be
similar.
Conclusions. In prosthetic valve thrombosis, the size of
thrombus is a significant independent predictor of outcome.
Transesophageal echocardiography is, therefore, recom-
mended in the management of PVT because it can identify
low-risk groups for thrombolysis, irrespective of severity of
symptoms, in whom thrombolysis may be used as first-line
therapy.
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